Centessa Pharmaceuticals (CNTA) was downgraded by Truist Financial Corporation from "buy" to "hold". They now have a $38.00 price target on the stock.
Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders
Centessa Pharmaceuticals (CNTA) had its "neutral" rating reaffirmed by Guggenheim.
Centessa Pharmaceuticals (CNTA) was downgraded by B. Riley Financial, Inc. from "strong-buy" to "hold".
Centessa Pharmaceuticals (CNTA) was downgraded by Lifesci Capital from "strong-buy" to "hold".